{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:38:56Z","timestamp":1760060336358,"version":"build-2065373602"},"reference-count":49,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Low-density lipoprotein cholesterol (LDL-C) reduction is critical for cardiovascular disease (CVD) prevention. This study aimed to assess the proportion of patients achieving the LDL-C target in Lithuania and to identify factors associated with target achievement. Materials and Methods: This retrospective study used anonymized health data from the Electronic Health Services and Cooperation Infrastructure Information System (ESPBI IS) in Lithuania. Adults aged \u226540 years with at least one LDL-C measurement in 2023 and no documented cancer diagnosis were included. The primary outcome was the proportion of patients achieving LDL-C &lt; 1.8 mmol\/L, the target recommended by the European Society of Cardiology guidelines for high-risk individuals. Univariate logistic regression analysis was conducted to identify factors associated with achieving the LDL-C target. Results: The study included 396,835 patients (mean age, 66.9 years). The mean LDL-C concentration was 3.32 mmol\/L, and only 8.1% of patients achieved LDL-C &lt; 1.8 mmol\/L. Target achievement was higher among patients in the secondary CVD prevention group compared to primary prevention (20.6% vs. 7.3%). Over half of patients (56.4%) received no lipid-lowering therapy (LLT). Statin monotherapy was the most prescribed LLT (31.3%), while only 2.7% of patients received statin and ezetimibe combination. In logistic regression analysis, secondary prevention status, more frequent cardiologist consultations, and higher LLT prescription frequency were associated with LDL-C target achievement. Compared to patients not receiving LLT, the odds of achieving LDL-C &lt; 1.8 mmol\/L were significantly higher in those receiving statin monotherapy (odds ratio [OR]: 3.153, 95% confidence interval [CI]: 3.069\u20133.240), statin and ezetimibe (OR: 7.631, 95% CI: 7.267\u20138.013), or statin and antihypertensive (OR: 3.945, 95% CI: 3.803\u20134.092). Conclusions: LDL-C target attainment remains low in Lithuania, with the underuse of LLT. Broader implementation of guideline-recommended lipid-lowering strategies is needed to improve LDL-C control.<\/jats:p>","DOI":"10.3390\/medicina61081484","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T07:56:06Z","timestamp":1755590166000},"page":"1484","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-Density Lipoprotein Cholesterol Target Attainment in Lithuania: A Nationwide Analysis of Real-World Health Data"],"prefix":"10.3390","volume":"61","author":[{"given":"Gediminas","family":"Urbonas","sequence":"first","affiliation":[{"name":"Department of Family Medicine, Medical Academy, Lithuanian University of Health Sciences, Eiveni\u0173 2, 50161 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7726-6948","authenticated-orcid":false,"given":"Tomas","family":"Lapinskas","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Eiveni\u0173 2, 50161 Kaunas, Lithuania"},{"name":"Lithuanian Society of Cardiology, Eiveni\u0173 2, 50161 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1975-8412","authenticated-orcid":false,"given":"Indr\u0117","family":"\u010ceponien\u0117","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Eiveni\u0173 2, 50161 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8035-564X","authenticated-orcid":false,"given":"Olga","family":"Vasiliauskien\u0117","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Medical Academy, Lithuanian University of Health Sciences, Eiveni\u0173 2, 50161 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Umbrasien\u0117","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Saules Seimos Medicinos Centras, Partizan\u0173 27D, 49449 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6117-6307","authenticated-orcid":false,"given":"Ingrida","family":"Grabauskyt\u0117","sequence":"additional","affiliation":[{"name":"Department of Physics, Mathematics and Biophysics, Lithuanian University of Health Sciences, Eiveni\u0173 4, 50103 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurgita","family":"Plisien\u0117","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Eiveni\u0173 2, 50161 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.clinthera.2023.09.020","article-title":"Global Trends in Atherosclerotic Cardiovascular Disease","volume":"45","author":"Nedkoff","year":"2023","journal-title":"Clin. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Chapman","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"118540","DOI":"10.1016\/j.atherosclerosis.2024.118540","article-title":"Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60 randomized controlled trials","volume":"396","author":"Burger","year":"2024","journal-title":"Atherosclerosis"},{"doi-asserted-by":"crossref","unstructured":"(2002). NCEP Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 106, 3143\u20133421.","key":"ref_5","DOI":"10.1161\/circ.106.25.3143"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"doi-asserted-by":"crossref","unstructured":"Banach, M., Jaiswal, V., Ang, S.P., Sawhney, A., Deb, N., Amarenco, P., Gaita, D., Reiner, Z., Pe\u0107in, I., and Lavie, C.J. (2025). Impact of Lipid-Lowering Combination Therapy with Statins and Ezetimibe vs Statin Monotherapy on the Reduction of Cardiovascular Outcomes: A Meta-analysis. Mayo Clin. Proc.","key":"ref_7","DOI":"10.1016\/j.mayocp.2025.01.018"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100649","DOI":"10.1016\/j.ajpc.2024.100649","article-title":"The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better","volume":"18","author":"Mhaimeed","year":"2024","journal-title":"Am. J. Prev. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40265-024-02113-5","article-title":"Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy","volume":"85","author":"Li","year":"2025","journal-title":"Drugs"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.2174\/0929867330666221129094921","article-title":"Effect of Statins on the Blood Lipid Profile in Patients with Different Cardiovascular Diseases: A Systematic Review with Meta-analysis of Randomized Clinical Trials","volume":"30","author":"Aslani","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.2015.15629","article-title":"Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force","volume":"316","author":"Chou","year":"2016","journal-title":"JAMA"},{"key":"ref_13","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"2013","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ahj.2018.12.007","article-title":"Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants","volume":"210","author":"Yebyo","year":"2019","journal-title":"Am. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/jep.12663","article-title":"Addition of Ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patient-important outcomes","volume":"24","author":"Fei","year":"2018","journal-title":"J. Eval. Clin. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e24334","DOI":"10.1002\/clc.24334","article-title":"Safety and Effectiveness of High-Intensity Statins Versus Low\/Moderate-Intensity Statins Plus Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease for Reaching LDL-C Goals: A Systematic Review and Meta-Analysis","volume":"47","author":"Soleimani","year":"2024","journal-title":"Clin. Cardiol."},{"key":"ref_17","first-page":"1602","article-title":"2023: The year in cardiovascular disease-the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?","volume":"19","author":"Banach","year":"2023","journal-title":"Arch. Med. Sci."},{"doi-asserted-by":"crossref","unstructured":"Urbonas, G., \u0160ileikien\u0117, L., Valius, L., Grigal\u0117, E., Kaupas, V., Ju\u0161ka, T., V\u0117brait\u0117, G., and Grabauskyt\u0117, I. (2024). Five-Year Trends in Low-Density Lipoprotein Cholesterol Management in a Primary Healthcare Centre in Kaunas. Medicina, 60.","key":"ref_18","DOI":"10.20944\/preprints202411.0117.v1"},{"doi-asserted-by":"crossref","unstructured":"Tamosiunas, A., Klumbiene, J., Petkeviciene, J., Radisauskas, R., Vikhireva, O., Luksiene, D., and Virviciute, D. (2016). Trends in major risk factors and mortality from main non-communicable diseases in Lithuania, 1985\u20132013. BMC Public Health, 16.","key":"ref_19","DOI":"10.1186\/s12889-016-3387-0"},{"doi-asserted-by":"crossref","unstructured":"Urbonas, G., Vencevi\u010dien\u0117, L., Valius, L., Krivickien\u0117, I., Petrauskas, L., Lazarenkien\u0117, G., Karpavi\u010dien\u0117, J., Bried\u0117, G., \u017du\u010denkien\u0117, E., and Vencevi\u010dius, K. (2020). Primary Prevention of Cardiovascular Risk in Lithuania-Results from EUROASPIRE V Survey. Medicina, 56.","key":"ref_20","DOI":"10.3390\/medicina56030134"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1080\/03007995.2021.1973396","article-title":"Lipid management across Europe in the real-world setting: A rapid evidence review","volume":"37","author":"Barrios","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: The DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1177\/2047487320908698","article-title":"Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries","volume":"28","author":"Kotseva","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2017.11.020","article-title":"Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany","volume":"268","author":"Dippel","year":"2018","journal-title":"Atherosclerosis"},{"doi-asserted-by":"crossref","unstructured":"Gavina, C., Carvalho, D.S., Pardal, M., Afonso-Silva, M., Grangeia, D., Dinis-Oliveira, R.J., Ara\u00fajo, F., and Taveira-Gomes, T. (2022). Cardiovascular Risk Profile and Lipid Management in the Population-Based Cohort Study LATINO: 20 Years of Real-World Data. J. Clin. Med., 11.","key":"ref_25","DOI":"10.3390\/jcm11226825"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: The multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e24330","DOI":"10.1002\/clc.24330","article-title":"Characteristics of Patients With Atherosclerotic Cardiovascular Disease in Belgium and Current Treatment Patterns for the Management of Elevated LDL-C Levels","volume":"47","author":"Maury","year":"2024","journal-title":"Clin. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.atherosclerosis.2019.03.017","article-title":"Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy","volume":"285","author":"Presta","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk","volume":"76","author":"Domanski","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jamacardio.2021.3508","article-title":"Association Between Cumulative Low-Density Lipoprotein Cholesterol Exposure During Young Adulthood and Middle Age and Risk of Cardiovascular Events","volume":"6","author":"Zhang","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"ref_32","first-page":"25","article-title":"Associations between the lipid profile and the development of hypertension in young individuals-the preliminary study","volume":"18","author":"Stemplewska","year":"2022","journal-title":"Arch. Med. Sci."},{"doi-asserted-by":"crossref","unstructured":"Hsu, H.Y., Lin, C.J., Lee, Y.S., Wu, T.H., and Chien, K.L. (2020). Efficacy of more intensive lipid-lowering therapy on cardiovascular diseases: A systematic review and meta-analysis. BMC Cardiovasc. Disord., 20.","key":"ref_33","DOI":"10.1186\/s12872-020-01567-1"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e008552","DOI":"10.1161\/CIRCOUTCOMES.121.008552","article-title":"Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis","volume":"15","author":"Wang","year":"2022","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"doi-asserted-by":"crossref","unstructured":"Halcox, J.P., Banegas, J.R., Roy, C., Dallongeville, J., De Backer, G., Guallar, E., Perk, J., Hajage, D., Henriksson, K.M., and Borghi, C. (2017). Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovasc. Disord., 17.","key":"ref_35","DOI":"10.1186\/s12872-017-0591-5"},{"doi-asserted-by":"crossref","unstructured":"Halcox, J.P., Tubach, F., Lopez-Garcia, E., De Backer, G., Borghi, C., Dallongeville, J., Guallar, E., Medina, J., Perk, J., and Sazova, O. (2015). Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe. PLoS ONE, 10.","key":"ref_36","DOI":"10.1371\/journal.pone.0115270"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.3399\/bjgp15X686113","article-title":"Statin prescribing for primary prevention of cardiovascular disease: A cross-sectional, observational study","volume":"65","author":"Homer","year":"2015","journal-title":"Br. J. Gen. Pr. Pract."},{"doi-asserted-by":"crossref","unstructured":"Ueda, P., Lung, T.W., Lu, Y., Salomon, J.A., Rahimi, K., Clarke, P., and Danaei, G. (2018). Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England. PLoS ONE, 13.","key":"ref_38","DOI":"10.1371\/journal.pone.0190688"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0002-9149(97)00679-6","article-title":"Treatment of hyperlipidemia by specialists versus generalists as secondary prevention of coronary artery disease","volume":"80","author":"Whyte","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3122\/15572625-11-3-180","article-title":"Cholesterol testing and management: A national comparison of family physicians, general internists, and cardiologists","volume":"11","author":"Eaton","year":"1998","journal-title":"J. Am. Board. Fam. Pract."},{"key":"ref_41","first-page":"684","article-title":"A qualitative study of barriers to the use of statins and the implementation of coronary heart disease prevention in primary care","volume":"53","author":"Kedward","year":"2003","journal-title":"Br. J. Gen. Pr. Pract."},{"doi-asserted-by":"crossref","unstructured":"Ah, Y.M., Jeong, M., and Choi, H.D. (2022). Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: A meta-analysis of randomized controlled studies. PLoS ONE, 17.","key":"ref_42","DOI":"10.1371\/journal.pone.0264437"},{"key":"ref_43","first-page":"805","article-title":"Adherence to lipid-lowering treatment: The patient perspective","volume":"6","author":"Casula","year":"2012","journal-title":"Patient Prefer. Adherence"},{"doi-asserted-by":"crossref","unstructured":"Fung, V., Graetz, I., Reed, M., and Jaffe, M.G. (2018). Patient-reported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk. PLoS ONE, 13.","key":"ref_44","DOI":"10.1371\/journal.pone.0191817"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.3399\/bjgp18X696365","article-title":"Patient beliefs and attitudes to taking statins: Systematic review of qualitative studies","volume":"68","author":"Ju","year":"2018","journal-title":"Br. J. Gen. Pract."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"i3305","DOI":"10.1136\/bmj.i3305","article-title":"Discontinuation and restarting in patients on statin treatment: Prospective open cohort study using a primary care database","volume":"353","author":"Vinogradova","year":"2016","journal-title":"BMJ"},{"doi-asserted-by":"crossref","unstructured":"Hope, H.F., Binkley, G.M., Fenton, S., Kitas, G.D., Verstappen, S.M.M., and Symmons, D.P.M. (2019). Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. PLoS ONE, 14.","key":"ref_47","DOI":"10.1371\/journal.pone.0201196"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e13861","DOI":"10.1111\/ijcp.13861","article-title":"Does management of lipid lowering differ between specialists and primary care: Insights from GOAL Canada","volume":"75","author":"Langer","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ejim.2009.04.002","article-title":"Coronary risk estimates and decisions on lipid-lowering treatment in primary prevention: Comparison between general practitioners, internists, and cardiologists","volume":"20","author":"Vancheri","year":"2009","journal-title":"Eur. J. Intern. Med."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/8\/1484\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:30:29Z","timestamp":1760034629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/8\/1484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":49,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["medicina61081484"],"URL":"https:\/\/doi.org\/10.3390\/medicina61081484","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2025,8,19]]}}}